239 related articles for article (PubMed ID: 12761664)
1. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.
Chaston TB; Richardson DR
J Biol Inorg Chem; 2003 Apr; 8(4):427-38. PubMed ID: 12761664
[TBL] [Abstract][Full Text] [Related]
2. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
3. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR
Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383
[TBL] [Abstract][Full Text] [Related]
4. Future of toxicology--iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy.
Kalinowski DS; Richardson DR
Chem Res Toxicol; 2007 May; 20(5):715-20. PubMed ID: 17402750
[TBL] [Abstract][Full Text] [Related]
5. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class.
Lim CK; Kalinowski DS; Richardson DR
Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues.
Bernhardt PV; Caldwell LM; Chaston TB; Chin P; Richardson DR
J Biol Inorg Chem; 2003 Nov; 8(8):866-80. PubMed ID: 14564555
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation.
Chaston TB; Watts RN; Yuan J; Richardson DR
Clin Cancer Res; 2004 Nov; 10(21):7365-74. PubMed ID: 15534113
[TBL] [Abstract][Full Text] [Related]
8. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922
[TBL] [Abstract][Full Text] [Related]
10. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation.
Darnell G; Richardson DR
Blood; 1999 Jul; 94(2):781-92. PubMed ID: 10397746
[TBL] [Abstract][Full Text] [Related]
11. Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacy.
Bernhardt PV; Chin P; Richardson DR
J Biol Inorg Chem; 2001 Oct; 6(8):801-9. PubMed ID: 11713687
[TBL] [Abstract][Full Text] [Related]
12. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
13. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
Richardson DR; Milnes K
Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
[TBL] [Abstract][Full Text] [Related]
14. Iron catalysed assembly of an asymmetric mixed-ligand triple helicate.
Bernhardt PV; Chin P; Richardson DR
Dalton Trans; 2004 Oct; (20):3342-6. PubMed ID: 15483720
[TBL] [Abstract][Full Text] [Related]
15. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogues prevent damage to 2-deoxyribose mediated by ferric iron plus ascorbate.
Hermes-Lima M; Ponka P; Schulman HM
Biochim Biophys Acta; 2000 Oct; 1523(2-3):154-60. PubMed ID: 11042379
[TBL] [Abstract][Full Text] [Related]
16. Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands.
Bernhardt PV; Wilson GJ; Sharpe PC; Kalinowski DS; Richardson DR
J Biol Inorg Chem; 2008 Jan; 13(1):107-19. PubMed ID: 17899222
[TBL] [Abstract][Full Text] [Related]
17. Hydrazone chelators for the treatment of iron overload disorders: iron coordination chemistry and biological activity.
Bernhardt PV; Chin P; Sharpe PC; Richardson DR
Dalton Trans; 2007 Aug; (30):3232-44. PubMed ID: 17893768
[TBL] [Abstract][Full Text] [Related]
18. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
19. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents.
Richardson DR; Tran EH; Ponka P
Blood; 1995 Dec; 86(11):4295-306. PubMed ID: 7492790
[TBL] [Abstract][Full Text] [Related]
20. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.
Richardson DR; Mouralian C; Ponka P; Becker E
Biochim Biophys Acta; 2001 May; 1536(2-3):133-40. PubMed ID: 11406348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
